Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- New set-up for IT at Bayer
- Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
- Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
- Roche and Spark Therapeutics, Inc. announce extension of tender offer
- AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
Research & Development
- High-tech method for uniquely targeted gene therapy developed
- The new polymer can kill drug-resistant bacteria
- A vaccine against chronic inflammatory diseases
- Microcapsules for targeted drug delivery to cancer cells
- Leukemia, lymphoma squarely in sights of new class of drugs
- First investigational drug therapy for liver disease NASH awaiting FDA approval
- The gut may be involved in the development of multiple sclerosis
Conferences & Events
- Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
- SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
- SMi's 4th Annual 3D Cell Culture
- Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
- RNA Therapeutics Conference and Focus Day
- CPhI Worldwide announces the winners of the 16th Pharma Awards
- CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023
Regulatory Affairs
- FDA launches app for health care professionals
- FDA approves first generics of Gilenya
- FDA approves novel treatment to target abnormality in sickle cell disease
- FDA approves first treatment for inherited rare disease
- FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease